Poland· PL-100345078
Evotaz
A atazanavir and cobicistat product containing atazanavirum + cobicistatum, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Atazanavir and cobicistat is registered in 11 of 19 countries.
Countries holding a registration under ATC J05AR15 (atazanavir and cobicistat), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Atazanavir and cobicistat · ATC J05AR15
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Atazanavirum + Cobicistatum
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Poland (PL)
- ATC code
- J05AR15
- ATC class
- Atazanavir and cobicistat
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991224400
- gtin05909991224417
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Atazanavir and cobicistat in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEVOTAZBristol-Myers Squibb Pharma EEIG, Dublin
- SpainEVOTAZ 300 MG/150 MG COMPRIMIDOS RECUBIERTOS CON PELICULABristol-Myers Squibb Pharma Eeig
- FinlandEVOTAZBristol-Myers Squibb Pharma EEIG
- United KingdomEvotaz 300mg/150mg tabletsBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandEVOTAZ 300 mg/150 mg film-coated tabletsBristol-Myers Squibb Pharma EEIG
- IcelandEvotazBristol-Myers Squibb Pharma EEIG*
- NetherlandsEVOTAZ 300 mg/150 mg filmomhulde tablettenBristol-Myers Squibb Pharma EEIG
- SwedenEVOTAZ 300 mg/150 mg Filmdragerad tablettBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Evotaz
- Liechtenstein · Evotaz
- Norway · Evotaz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b7519d02-490e-4f14-a142-8be60ec3aab4 GET /v1/drugs/b7519d02-490e-4f14-a142-8be60ec3aab4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "300 mg + 150 mg",
"packaging": "05909991224400 ¦ Rpz ¦ EU/1/15/1025/001 ¦ 108689\n30 tabl.\n05909991224417 ¦ Rpz ¦ EU/1/15/1025/002 ¦ 108690\n90 tabl.",
"substance": "Atazanavirum 300 mg + Cobicistatum 150 mg",
"common_name": "Atazanavirum + Cobicistatum",
"pl_product_id": "100345078",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about atazanavir and cobicistat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.